Crystal forms of demethyleneberberine hydrochloride and preparation method therefor

1. A crystal form of demethyleneberberine hydrochloride selected from:

A) a crystal form designated as crystal form A, characterized in that, it has characteristic diffraction peaks at 6.838, 8.300, 12.477, 13.667, 16.269, 16.642, 17.761, 18.247, 18.749, 20.389, 20.739, 21.926, 22.530, 23.983, 24.819, 25.774, 26.413, 26.592, 28.552, 30.333, and 38.312° in an X-ray powder diffraction spectrum represented by Cu-Kα radiation and 20±0.2° diffraction angle; one thermal absorption peak at 240±3° C. in a DSC thermogram; and characteristic infrared absorption peaks at 422.8 cm −1 , 454.3 cm −1 , 466.6 cm −1 , 505.6 cm −1 , 581.8 cm −1 , 617.7 cm −1 , 658.5 cm −1 , 739.3 cm −1 , 774.6 cm −1 , 820.3 cm −1 , 871.8 cm −1 , 892.6 cm −1 , 917.5 cm −1 , 962.6 cm −1 , 983.2 cm −1 , 999.7 cm −1 , 1,050.0 cm −1 , 1,067.8 cm −1 , 1,110.5 cm −1 , 1,140.5 cm −1 , 1,203.4 cm −1 , 1,244.5 cm −1 , 1,268.1 cm −1 , 1,293.8 cm −1 , 1,337.1 cm −1 , 1,363.8 cm −1 , 1,390.5 cm −1 , 1,455.5 cm −1 , 1,493.9 cm −1 , 1,515.6 cm −1 , 1,530.5 cm −1 , 1,567.1 cm −1 , 1,605.6 cm −1 , 1,638.0 cm −1 , 1,769.6 cm −1 , 2,726.3 cm −1 , 2,847.6 cm −1 , 2,945.2 cm −1 , 3,024.2 cm −1 , 3,065.1 cm −1 , 3,086.0 cm −1 , and 3,150.6 cm −1 ;

B) a crystal form designated as crystal form B, characterized in that, it has characteristic diffraction peaks at 6.838, 8.300, 12.477, 13.667, 16.269, 16.642, 17.761, 18.247, 18.749, 20.389, 20.739, 21.926, 22.530, 23.983, 24.819, 25.774, 26.413, 26.592, 28.552, 30.333, and 38.312° in an X-ray powder diffraction spectrum represented by Cu-Kα radiation and 20±0.2° diffraction angle; two thermal absorption peaks at 147±3° C. and 220±3° C. respectively in a DSC thermogram; and characteristic infrared absorption peaks at 421.5 cm −1 , 448.0 cm −1 , 464.4 cm −1 , 506.1 cm −1 , 523.9 cm −1 , 543.5 cm −1 , 568.8 cm −1 , 583.9 cm −1 , 618.9 cm −1 , 649.1 cm −1 , 676.8 cm −1 , 718.3 cm −1 , 742.1 cm −1 , 777.5 cm −1 , 833.0 cm −1 , 859.8 cm −1 , 878.7 cm −1 , 924.5 cm −1 , 960.4 cm −1 , 977.7 cm −1 , 1,018.9 cm −1 , 1,060.0 cm −1 , 1,107.7 cm −1 , 1,138.4 cm −1 , 1,170.1 cm −1 , 1,207.4 cm −1 , 1,243.9 cm −1 , 1,268.6 cm −1 , 1,366.8 cm −1 , 1,388.7 cm −1 , 1,422.7 cm −1 , 1,445.5 cm −1 , 1,457.3 cm −1 , 1,492.8 cm −1 , 1,517.8 cm −1 , 1,533.9 cm −1 , 1,568.8 cm −1 , 1,610.9 cm −1 , 1,636.9 cm −1 , 1,735.5 cm −1 , 2,646.6 cm −1 , 2,849.8 cm −1 , 2,952.5 cm −1 , 2,993.5 cm −1 , 3,089.6 cm −1 , and 3,364.3 cm −1 ;

C) a crystal form designated as crystal form C, characterized in that, it has characteristic diffraction peaks at 3.260, 8.515, 9.715, 12.147, 13.219, 14.789, 17.607, 18.306, 20.728, 21.261, 24.633, 25.430, 25.837, 26.416, 27.606, 28.147, and 37.695° in an X-ray powder diffraction spectrum represented by Cu-Kα radiation and 20±0.2° diffraction angle; one thermal absorption peak at 253±3° C. in a DSC thermogram; and characteristic infrared absorption peaks at 422.8 cm −1 , 441.6 cm −1 , 452.2 cm −1 , 505.0 cm −1 , 526.2 cm −1 , 584.6 cm −1 , 637.3 cm −1 , 652.0 cm −1 , 665.7 cm −1 , 699.9 cm −1 , 723.4 cm −1 , 742.0 cm −1 , 774.1 cm −1 , 814.2 cm −1 , 828.2 cm −1 , 869.6 cm −1 , 891.7 cm −1 , 915.6 cm −1 , 964.5 cm −1 , 980.6 cm −1 , 998.8 cm −1 , 1,065.8 cm −1 , 1,108.5 cm −1 , 1,139.7 cm −1 , 1,192.2 cm −1 , 1,216.5 cm −1 , 1,241.0 cm −1 , 1,273.9 cm −1 , 1,287.4 cm −1 , 1,308.2 cm −1 , 1,343.5 cm −1 , 1,356.5 cm −1 , 1,389.3 cm −1 , 1,420.2 cm −1 , 1,437.9 cm −1 , 1,456.1 cm −1 , 1,510.2 cm −1 , 1,565.5 cm −1 , 1,580.9 cm −1 , 1,604.3 cm −1 , 1,618.6 cm −1 , 1,633.2 cm −1 , 2,697.9 cm −1 , 2,842.7 cm −1 , 2,946.1 cm −1 , 3,005.3 cm −1 , and 3,066.4 cm −1 ; and

D) a crystal form designated as crystal form D, characterized in that, it has characteristic diffraction peaks at about 6.034, 8.699, 12.589, 18.108, 21.854, 24.224, 25.146 and 26.172° in an X-ray powder diffraction spectrum represented by Cu-Kα radiation and 2θ diffraction angle; two thermal absorption peaks at 131±3° C. and 190±3° C. respectively in a DSC thermogram; and characteristic infrared absorption peaks at 422.8 cm −1 , 454.3 cm −1 , 466.6 cm −1 , 505.6 cm −1 , 581.8 cm −1 , 617.7 cm −1 , 658.5 cm −1 , 739.3 cm −1 , 774.6 cm −1 , 820.3 cm −1 , 871.8 cm −1 , 892.6 cm −1 , 917.5 cm −1 , 962.6 cm −1 , 983.2 cm −1 , 999.7 cm −1 , 1,050.0 cm −1 , 1,067.8 cm −1 , 1,110.5 cm −1 , 1,140.5 cm −1 , 1,203.4 cm −1 , 1,244.5 cm −1 , 1,268.1 cm −1 , 1,293.8 cm −1 , 1,337.1 cm −1 , 1,363.8 cm −1 , 1,390.5 cm −1 , 1,455.5 cm −1 , 1,493.9 cm −1 , 1,515.6 cm −1 , 1,530.5 cm −1 , 1,567.2 cm −1 , 1,605.6 cm −1 , 1,638.0 cm −1 , 1,769.6 cm −1 , 2,726.3 cm −1 , 2,847.6 cm −1 , 2,945.2 cm −1 , 3,024.2 cm −1 , 3,065.1 cm −1 , 3,086.0 cm −1 , and 3,150.6 cm −1 .

2. A method for preparing the crystal foil is of demethyleneberberine hydrochloride according to claim 1 , comprising the following steps:

(1) adding 4 g of phloroglucinol into 100 ml of 40%-60% sulfuric acid, and stirring, so that the phloroglucinol is dissolved;

(2) adding 5 g of berberine hydrochloride into the solution obtained in the step (1), and stirring for 2 h at 80° C.-100° C.;

(3) adding the solution obtained in the step (2) into 100 ml of saturated salt solution, and stirring for 2 h;

(4) filtering the mixed solution obtained in the step (3) by suction-filtration, dissolving filter cake with 100 ml of methanol in water bath at 70° C., and recrystallizing;

(5) filtering the solution obtained in the step (4) by suction-filtration, dissolving filter cake with 100 ml of methanol in water bath at 70° C., recrystallizing, and performing suction-filtration;

(6) drying a yellow solid obtained in the step (5) by vacuum drying for 24 h at room temperature, so that a crystal form B of demethyleneberberine hydrochloride is obtained;

(7) filtering the solution obtained in the step (4) by suction-filtration, dissolving filter cake with 100 ml of ethanol in water bath at 80° C., recrystallizing, and performing suction-filtration;

(8) drying a yellow solid obtained in the step (7) by vacuum drying for 24 h at room temperature, so that a crystal form C of demethyleneberberine hydrochloride is obtained;

(9) filtering the solution obtained in the step (4) by suction-filtration, dissolving 1 g of filter cake with 12 ml of ethanol in water bath at 80° C. while stirring, performing suction-filtration and collecting filter cake;

(10) drying a yellow solid obtained in the step (9) by vacuum drying for 24 h at room temperature, so that a crystal form A of demethyleneberberine hydrochloride is obtained;

(11) filtering the solution obtained in the step (4) by suction-filtration, dissolving 1 g of filter cake with 30 ml of deionized water in water bath at 74° C. while stirring, recrystallizing, and performing suction-filtration; and

(12) drying a yellow solid obtained in the step (11) by vacuum freeze-drying for 48 h, so that a crystal form D of demethyleneberberine hydrochloride is obtained.

3. The method for preparing the crystal forms of demethyleneberberine hydrochloride according to claim 2 , wherein the step (5) further comprises: adding a small amount of seed crystals, adding 10-20 vol. % of diethyl ether, adding 10-20 vol. % of xylene, and adding 10-20 vol. % of toluene.

4. The method for preparing the crystal form of demethyleneberberine hydrochloride according to claim 2 , wherein the step (7) further comprises: adding a small amount of seed crystals, adding 10-20 vol. % of diethyl ether, adding 10-20 vol. % of xylene, and adding 10-20 vol. % of toluene.

5. A pharmaceutical composition comprising crystal form A, B, C and/or D of demethyleneberberine hydrochloride according claim 1 .

6. The pharmaceutical composition, according to claim 5 , formulated as a tablet, capsule, pill or as a sustained-release agent, or for injection, or as a microparticle administration system.

7. A method for treating liver fibrosis, acute and/or chronic alcoholic liver disease, ulcerative colitis, an immune liver injury and/or a nonalcoholic fatty liver disease, wherein said method comprises administering, to a subject in need of such treatment, a crystal form of demethyleneberberine hydrochloride according to claim 1 .

8. A method for providing a hypoglycemic effect and/or for treating diabetes, wherein said method comprises administering, to a subject in need of such treatment, a crystal faun of demethyleneberberine hydrochloride according to claim 1 .